Cancer diagnostics News and Research

RSS

Active surveillance sufficient for patients with low-risk prostate cancer

Active surveillance or watchful waiting might be sufficient treatment for patients with prostate cancer that has a low risk of progression, according to a new study published online June 18 in The Journal of the National Cancer Institute.

19 Jun 2010

ASTRO urges MedPAC to recommend end to abuse of physician self-referral law in radiation oncology

The American Society for Radiation Oncology (ASTRO) commends the Medicare Payment Advisory Commission (MedPAC) for highlighting concerns about physician self-referral in cancer care in its report released yesterday. We urge the commission to make recommendations to Congress to end abuses of the physician self-referral law in radiation oncology enabled by the "in-office ancillary services exception."

17 Jun 2010

Exercise helps patients recover shoulder movement after breast cancer surgery

An active 72-year-old woman, Claire Mitchell had always enjoyed cooking. However, after breast cancer surgery she found that she had less freedom of movement and reaching jars on high shelves became quite painful. Her plight is common.

16 Jun 2010

Course on cancer rehabilitation for nurses and other health professionals

Nurses and other health professionals will soon be able to take a dedicated course on cancer rehabilitation at Swansea University. The master's module in cancer rehabilitation is being launched to help the training of health and social care staff.

16 Jun 2010

Researchers examine rates of cancer in British white and British Indian population

British Indians have fewer cases of many different cancers including breast, prostate, colon and lung than the British white population, according to new research published in the British Journal of Cancer1 today (Wednesday).

16 Jun 2010

Best gift for Father's Day: CISRC

While Father's Day gifts range from the touching to the hilarious, the best gift you might give your father or spouse is help and support during the difficult time of a cancer diagnosis.

15 Jun 2010

Fluorescent cancerous tumors for early detection

Researchers at the Ecole Polytechnique F-d-rale de Lausanne (EPFL) in Switzerland have established a procedure where cancerous tumors in the bladder become fluorescent and are more easily discoverable under blue light. The Food and Drug Administration (FDA) approved the technique- already in practice in Europe - for the American market. Under the name Cysview-, the product is commercialized by Photocure and GE Healthcare as the most efficient detection technique for early stage bladder cancer.

14 Jun 2010

Telmisartan reduces hypertension, cardiovascular risk in ACE-intolerant patients: Boehringer Ingelheim

Telmisartan, an angiotensin receptor blocker, is one of the best researched drugs worldwide. It has been studied in clinical trials in more than 50,000 patients. Its positive safety profile has been confirmed also in a market exposure of 34.5 million patient years. Convincing safety data for patients with a high cardiovascular risk were collected in the three long-term outcome trials ONTARGET, PRoFESS and TRANSCEND which followed some of the patients for up to five years.

14 Jun 2010

New guideline to improve IHC testing for expression status of ER and PgR in breast cancer issued

The College of American Pathologists and the American Society of Clinical Oncology today issued a joint guideline aimed at improving the accuracy of immunohistochemistry testing for the expression status of estrogen and progesterone receptors in breast cancer. The two groups conducted a systematic review of medical research literature in partnership with Cancer Care Ontario to develop the recommendations.

14 Jun 2010

PAF launches CINV CareLine to assist patients with cancer, CINV

Patient Advocate Foundation – a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of their financial stability relative to their diagnosis of life threatening or debilitating diseases – is pleased to announce that it has launched a new program, the CINV CareLine.

11 Jun 2010

Psychological intervention program teaches breast cancer patients how to cope with the disease

A psychological intervention program designed for breast cancer patients reduces the risk of dying if the cancer recurs, new research shows. The study is the latest in a series at Ohio State University that have shown that an intervention program that teaches patients how to cope with the disease can boost their health, well-being and even their chances of survival.

9 Jun 2010

Clarient granted U.K. patent for TLE3 biomarker

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the United Kingdom Patent Office has granted a U.K. patent on the Company's TLE3 biomarker, a marker which may be used to predict which cancer patients will respond favorably to taxane therapy.

8 Jun 2010

CancerForward: The Foundation for Cancer Survivors launched

The numbers are stark. An astounding three out of every four U.S. families include one family member diagnosed with cancer. Worldwide, 28 million people - more than 12 million people in the U.S. alone - are now living with cancer. While the survivor population continues to grow, few public resources exist to promote the exchange of education and experiential information among survivors.

7 Jun 2010

Biomoda granted Mexican patent for proprietary porphyrin-based compound

Cancer diagnostics company Biomoda, Inc. has been granted a Mexican patent for its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce red under ultraviolet light.

7 Jun 2010

Microscopic image sensor to speed up detection of tumors

To diagnose cancer reliably, doctors usually conduct a biopsy including tissue ana-lysis - which is a time-consuming process. A microscopic image sensor, fitted in an endoscope, is being developed for in vivo cancer diagnosis, to speed up the detection of tumors.

7 Jun 2010

New molecular imaging agent improves diagnosis of recurrent prostate cancer

Findings of a clinical trial reported at SNM's 57th Annual Meeting indicate that a new molecular imaging agent could improve diagnosis of recurrent prostate cancer and determine the best possible course of treatment for patients.

7 Jun 2010

Multiple study data on Agendia's MammaPrint, BluePrint, and ColoPrint assays to be presented at 2010 ASCO

Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic centers in the U.S. and Europe will present data from multiple studies concerning Agendia's assays MammaPrint(R), BluePrint(TM), and ColoPrint(TM) at the American Society of Clinical Oncology Annual Meeting, June 4 - 8, 2010, at McCormick Place in Chicago. MammaPrint, the company's lead product, is the only FDA-cleared breast cancer recurrence test.

5 Jun 2010

PEB's European licensee SDX completes clinical trial for prognostic gene signature for colorectal cancer

Pacific Edge (PEB), a New Zealand-based biomedical company, today announced the successful completion of the European clinical trial for their prognostic gene signature for colorectal cancer. The clinical trial results showed a successful outcome that enables patients diagnosed with UICC stage II or UICC stage III colorectal cancer and with a high risk of disease progression to be identified and treated more appropriately.

5 Jun 2010

Biomoda, Obio sign MOU to establish CLIA-certified clinical laboratory in Ohio

Cancer diagnostics company Biomoda, Inc. and Obio, a corporation formed to pursue public and private funding for cancer research in Ohio, signed a memorandum of understanding to establish a CLIA-certified Biomoda clinical laboratory in Ohio to support ongoing research and development on Biomoda's porphyrin-based assay for the detection of early-stage cancer.

2 Jun 2010

Study demonstrates diagnostic, economic benefits of AABT for lung cancer patients

Oncimmune LLC, maker of EarlyCDT-Lung, a simple blood test that aids physicians in risk assessment and the early detection of lung cancer, today announced validation study results demonstrating the diagnostic and economic benefits of a standardized and reproducible autoantibody laboratory test that may significantly improve the prognosis for lung cancer patients.

2 Jun 2010

Cancer diagnostics News and Research

Active surveillance sufficient for patients with low-risk prostate cancer

ASTRO urges MedPAC to recommend end to abuse of physician self-referral law in radiation oncology

Exercise helps patients recover shoulder movement after breast cancer surgery

Course on cancer rehabilitation for nurses and other health professionals

Researchers examine rates of cancer in British white and British Indian population

Best gift for Father's Day: CISRC

Fluorescent cancerous tumors for early detection

Telmisartan reduces hypertension, cardiovascular risk in ACE-intolerant patients: Boehringer Ingelheim

New guideline to improve IHC testing for expression status of ER and PgR in breast cancer issued

PAF launches CINV CareLine to assist patients with cancer, CINV

Psychological intervention program teaches breast cancer patients how to cope with the disease

Clarient granted U.K. patent for TLE3 biomarker

CancerForward: The Foundation for Cancer Survivors launched

Biomoda granted Mexican patent for proprietary porphyrin-based compound

Microscopic image sensor to speed up detection of tumors

New molecular imaging agent improves diagnosis of recurrent prostate cancer

Multiple study data on Agendia's MammaPrint, BluePrint, and ColoPrint assays to be presented at 2010 ASCO

PEB's European licensee SDX completes clinical trial for prognostic gene signature for colorectal cancer

Biomoda, Obio sign MOU to establish CLIA-certified clinical laboratory in Ohio

Study demonstrates diagnostic, economic benefits of AABT for lung cancer patients

eBook: Liquid biopsy in cancer research eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News